Industry
Biotechnology
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Loading...
Open
1.94
Mkt cap
3.6M
Volume
72K
High
1.95
P/E Ratio
0.23
52-wk high
17.75
Low
1.82
Div yield
N/A
52-wk low
1.16
Portfolio Pulse from Benzinga Insights
October 25, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:38 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:35 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 3:22 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 2:51 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 2:46 pm
Portfolio Pulse from Benzinga Insights
October 17, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
October 17, 2024 | 1:57 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.